Home › Cancro al seno triplo negativo › Minnesota › Minneapolis
Studi clinici su Cancro al seno triplo negativo a Minneapolis, MN
8 studi su Cancro al seno triplo negativo cercano partecipanti presso sedi a Minneapolis e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
PRE-ISPY Phase I/II Oncology Platform Program
In reclutamentoFase 1/2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
In reclutamentoFase 3
- Allina Health Cancer Institute ( Site 0069), Minneapolis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
In reclutamentoFase 3
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park · a 5 mi di distanza
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
In reclutamentoFase 3
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- Metro Minnesota Community Oncology, Saint Louis Park · a 5 mi di distanza
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
In reclutamentoFase 1
- Normunity Investigational Site, Minneapolis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
In reclutamentoFase 2/3
- Local Institution - 0372, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
In reclutamentoFase 2
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · a 5 mi di distanza
Studi su Cancro al seno triplo negativo in altre città
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Altri studi a Minneapolis
- Cancro del polmone non a piccole cellule27 studi
- Cancro al seno27 studi
- Cancro ovarico24 studi
- Cancro alla prostata23 studi
- Cancro (tutti i tipi)22 studi
- Insufficienza cardiaca21 studi
- Leucemia mieloide acuta20 studi
- Cancro ai polmoni20 studi
- Cancro colorettale19 studi
- Cancro dell'endometrio18 studi
- Morbo di Parkinson17 studi
- Malattie cardiovascolari15 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.